Robin Respaut is a Healthcare Reporter at Reuters. She specializes in healthcare, finance, and data journalism, providing in-depth analysis and insights on these critical topics. Her work has been featured in notable publications such as the St. Louis Post-Dispatch, USA TODAY, and Medscape, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Robin Respaut's coverage primarily revolves around healthcare, pharmaceuticals, and mental health. She often cites government announcements and data while also providing exclusive insights into evolving stories within the healthcare industry.
If you are reaching out to Robin, it would be beneficial to offer expert opinions on government policies or regulations related to healthcare and pharmaceuticals. Additionally, if you have access to exclusive data or can provide insights into emerging trends in the healthcare sector, your pitch is likely to capture her interest.
Given that Robin doesn't specify a geographic focus, she may cover international as well as national topics within the scope of healthcare and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Bhanvi Satija, Robin Respaut
Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo Nordisk to manage the hormonal disorder's symptoms, according to an exclusive analysis of U.S. patient records and interviews with obesity specialists and...
Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo Nordisk to manage the hormonal disorder's symptoms.
By: Robin Respaut
SAN FRANCISCO, Feb 11 (Reuters) - Among early users of Novo Nordisk'snew Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
Among early users of Novo Nordisk's new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new nationwide study from the health data firm Truveta found.
By: Robin Respaut
March 3 (Reuters) - Autism researchers and advocacy leaders on Tuesday said they would form a new, independent committee to help guide autism research priorities, providing a science-based alternative to official U.S. information on the condition.
By: Robin Respaut
By Robin Respaut April 28 (Reuters) - A U.S. advisory committee appointed by Health Secretary Robert F.
By: Robin Respaut
A U.S. advisory committee appointed by Health Secretary Robert F. Kennedy Jr. recommended on Tuesday that the government adopt the term "profound autism” for those with the...
By: Robin Respaut
By Robin Respaut SAN FRANCISCO, Aug 12 (Reuters) - Eli Lilly on Wednesday said it had filed six lawsuits against U.S. companies it accuses
By: Robin Respaut
By Robin Respaut SAN FRANCISCO, Aug 16 (Reuters) - U.S. Attorney General Todd Blanche said on Sunday that he backs top Washington, D.C., prosecutor
By: Robin Respaut
An advisory committee on autism adopted a new strategic plan on Thursday that calls on federal agencies to nearly double investment in research and initiatives focusing on medical care, housing, aging, and other priorities to support people with the condition and their families.
